Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AI-09 in Glabellar Lines
NCT05565950Phase 2Completed
- Sponsor
- Eirion Therapeutics
- Start
- Oct 2022
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of AI-09 in glabellar lines, sponsored by Eirion Therapeutics. Started Oct 2022; status: completed.
02
Drugs
AI-09
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT05565950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05565950.